세계의 데스모이드 종양 시장 보고서(2025년)

Desmoid tumors are rare non-cancerous (benign) growths originating from connective tissue cells, typically within the fascia- the tissue encompassing muscles, nerves, and blood vessels. Although locally aggressive, meaning they can grow and invade nearby structures, desmoid tumors differ from traditional cancers as they do not metastasize to distant parts of the body.

The primary treatments for desmoid tumors encompass surgical intervention, radiation therapy, anti-inflammatory medications, hormone therapy, chemotherapy, novel molecular-targeted therapy, and other therapeutic approaches. Surgery involves the removal or repair of tissues or organs within the body. The diagnosis of desmoid tumors employs various methods such as biopsy, electron microscopic examination, immunohistochemical analysis, and others. Medical professionals in hospitals, clinics, specialty centers, and similar healthcare facilities typically undertake these diagnostic and treatment procedures.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The desmoid tumors market research report is one of a series of new reports from The Business Research Company that provides desmoid tumors market statistics, including desmoid tumors industry global market size, regional shares, competitors with a desmoid tumors market share, detailed desmoid tumors market segments, market trends and opportunities, and any further data you may need to thrive in the desmoid tumors industry. This desmoid tumors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The desmoid tumors market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to advancements in medical imaging, genetic research and understanding, surgical innovations, awareness and education, patient advocacy.

The desmoid tumors market size is expected to see strong growth in the next few years. It will grow to $4.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to targeted therapies, personalized medicine, expanded international collaborations, regulatory approvals for novel therapies, patient-centric approaches. Major trends in the forecast period include advancements in treatment approaches, precision medicine and biomarker discovery, clinical trials and research initiatives, multidisciplinary treatment teams, patient advocacy and support.

The forecast of 6.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. sarcoma care by inflating prices of gamma-secretase inhibitors and cryoablation equipment developed in the UK and Japan, resulting in delayed aggressive fibromatosis treatment and higher oncology expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of cancer is anticipated to drive the growth of the desmoid tumor market in the future. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and organs, causing significant harm. The global rise in cancer cases has spurred demand for advanced and effective chemotherapeutic agents, positively impacting the desmoid tumor market. For example, in May 2024, according to the National Cancer Institute, a U.S.-based federal government agency, an estimated 2,001,140 new cases of cancer are expected to be diagnosed in the U.S. in 2024, with 611,720 projected deaths from the disease. In 2022, nearly 20 million new cases and 9.7 million cancer-related deaths were reported worldwide. By 2040, the annual number of new cancer cases is expected to increase to 29.9 million, with cancer-related deaths projected to reach 15.3 million. Consequently, the rising cancer cases are driving the growth of the desmoid tumor market.

The increasing allocation of government funding for research and development is expected to boost the desmoid tumor market. Government funding plays a pivotal role in advancing tumor research and treatment by providing financial support for scientific studies, medical infrastructure, and improved access to care. This ultimately enhances cancer prevention, diagnosis, and patient outcomes. An example is the budget of $7.3 billion allocated to the National Cancer Institute by the United States Congress in fiscal year 2023 for the Cancer Moonshot, marking a $408 million increase from 2022. Consequently, the escalating government funding for research and development is fostering the growth of the desmoid tumor market.

Key companies in the desmoid tumors market are focusing on developing innovative drugs, such as nirogacestat, to address the needs of their existing consumers more effectively. Nirogacestat, an oral, small-molecule gamma-secretase inhibitor, has shown promise for treating desmoid tumors by blocking the production of notch proteins, contributing to tumor cell death. In February 2023, SpringWorks Therapeutics Inc. announced the acceptance and priority review of their new drug application (NDA) for nirogacestat by the U.S. Food and Drug Administration (FDA). This development provides patients with a new treatment option that holds the potential to improve outcomes.

In January 2023, the merger of Advaxis Inc. with Ayala Pharmaceuticals Inc., a US-based biotechnology company, aims to create a unified entity focused on developing and commercializing Ayala's lead program, AL102, for desmoid tumor treatment. The merger intends to expedite the development and commercialization of AL102, fostering a more diversified and robust cancer portfolio. Ayala Pharmaceuticals Inc. is actively developing AL102, a vaccine candidate designed to address the treatment of desmoid tumors.

Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the desmoid tumors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The desmoid tumors market consists of revenues earned by entities by providing services such as gleevec-based therapy, sorafenib-based therapy, long-term monitoring, resonance imaging (MRI), computed tomography (CT) scans, ultrasound, and fine needle aspiration techniques (FNA) that aid in the diagnosis of desmoid tumors. The market value includes the value of related goods sold by the service provider or included within the service offering. The desmoid tumors market also includes sales of surgical tools, linear accelerators, immunotherapy drugs, and anti-fibrotic agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Desmoid Tumors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on desmoid tumors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for desmoid tumors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The desmoid tumors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Surgery; Radiation Therapy; Anti-Inflammatory Medication; Hormone Therapy; Chemotherapy; Novel Molecular-Targeted Therapy; Other Treatments
• 2) By Diagnosis: Biopsy; Electron Microscopic Examination; Immunohistochemical Analysis; Other Diagnosis
• 3) By End-User: Hospitals And Clinics; Specialty Centers; Other End-Users
• Subsegments:
• 1) By Surgery: Wide Excision; Minimally Invasive Surgery
• 2) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy
• 3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids
• 4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors
• 5) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy
• 6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Therapies
• 7) By Other Treatments: Watchful Waiting; Physical Therapy; Pain Management Strategies
• Companies Mentioned: Pfizer Inc.; F.Hoffmann-La Roche Ltd.; Abbvie Inc.; Bayer AG; Novartis AG; Abbott Laboratories; Amgen Inc.; Stryker Corporation; Genome And Company ; Vertex Pharmaceuticals Incorporated; Eisai Limited; Beckman Coulter Inc.; Incyte Corporation ; Ipsen Biopharmaceuticals Inc.; BeiGene Ltd.; Janssen Biotech Inc.; Ionis Pharmaceuticals Inc.; Ayala Pharmaceuticals Inc.; Blueprint Medicines Corporation; Xencor Inc.; MacroGenics Inc.; Debiopharm Group; Clovis Oncology Inc.; Juno Therapeutics Inc.; SpringWorks Therapeutics Inc.; Loxo Oncology Inc.; Mirati Therapeutics Inc.; Iterion Therapeutics Inc.; Recepta Pharmaceuticals Inc.; Cellestia Biotech AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Desmoid Tumors Market Characteristics

3. Desmoid Tumors Market Trends And Strategies

4. Desmoid Tumors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Desmoid Tumors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Desmoid Tumors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Desmoid Tumors Market Growth Rate Analysis
• 5.4. Global Desmoid Tumors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Desmoid Tumors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Desmoid Tumors Total Addressable Market (TAM)

6. Desmoid Tumors Market Segmentation

• 6.1. Global Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Radiation Therapy
• Anti-Inflammatory Medication
• Hormone Therapy
• Chemotherapy
• Novel Molecular-Targeted Therapy
• Other Treatments
• 6.2. Global Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy
• Electron Microscopic Examination
• Immunohistochemical Analysis
• Other Diagnosis
• 6.3. Global Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Specialty Centers
• Other End-Users
• 6.4. Global Desmoid Tumors Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wide Excision
• Minimally Invasive Surgery
• 6.5. Global Desmoid Tumors Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Stereotactic Body Radiation Therapy
• 6.6. Global Desmoid Tumors Market, Sub-Segmentation Of Anti-Inflammatory Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• 6.7. Global Desmoid Tumors Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Estrogen Receptor Modulators (SERMs)
• Aromatase Inhibitors
• 6.8. Global Desmoid Tumors Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Traditional Chemotherapy Agents
• Combination Chemotherapy
• 6.9. Global Desmoid Tumors Market, Sub-Segmentation Of Novel Molecular-Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors
• Other Targeted Therapies
• 6.10. Global Desmoid Tumors Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Watchful Waiting
• Physical Therapy
• Pain Management Strategies

7. Desmoid Tumors Market Regional And Country Analysis

• 7.1. Global Desmoid Tumors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Desmoid Tumors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Desmoid Tumors Market

• 8.1. Asia-Pacific Desmoid Tumors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Desmoid Tumors Market

• 9.1. China Desmoid Tumors Market Overview
• 9.2. China Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Desmoid Tumors Market

• 10.1. India Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Desmoid Tumors Market

• 11.1. Japan Desmoid Tumors Market Overview
• 11.2. Japan Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Desmoid Tumors Market

• 12.1. Australia Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Desmoid Tumors Market

• 13.1. Indonesia Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Desmoid Tumors Market

• 14.1. South Korea Desmoid Tumors Market Overview
• 14.2. South Korea Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Desmoid Tumors Market

• 15.1. Western Europe Desmoid Tumors Market Overview
• 15.2. Western Europe Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Desmoid Tumors Market

• 16.1. UK Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Desmoid Tumors Market

• 17.1. Germany Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Desmoid Tumors Market

• 18.1. France Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Desmoid Tumors Market

• 19.1. Italy Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Desmoid Tumors Market

• 20.1. Spain Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Desmoid Tumors Market

• 21.1. Eastern Europe Desmoid Tumors Market Overview
• 21.2. Eastern Europe Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Desmoid Tumors Market

• 22.1. Russia Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Desmoid Tumors Market

• 23.1. North America Desmoid Tumors Market Overview
• 23.2. North America Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Desmoid Tumors Market

• 24.1. USA Desmoid Tumors Market Overview
• 24.2. USA Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Desmoid Tumors Market

• 25.1. Canada Desmoid Tumors Market Overview
• 25.2. Canada Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Desmoid Tumors Market

• 26.1. South America Desmoid Tumors Market Overview
• 26.2. South America Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Desmoid Tumors Market

• 27.1. Brazil Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Desmoid Tumors Market

• 28.1. Middle East Desmoid Tumors Market Overview
• 28.2. Middle East Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Desmoid Tumors Market

• 29.1. Africa Desmoid Tumors Market Overview
• 29.2. Africa Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Desmoid Tumors Market Competitive Landscape And Company Profiles

• 30.1. Desmoid Tumors Market Competitive Landscape
• 30.2. Desmoid Tumors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F.Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Desmoid Tumors Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Amgen Inc.
• 31.3. Stryker Corporation
• 31.4. Genome And Company
• 31.5. Vertex Pharmaceuticals Incorporated
• 31.6. Eisai Limited
• 31.7. Beckman Coulter Inc.
• 31.8. Incyte Corporation
• 31.9. Ipsen Biopharmaceuticals Inc.
• 31.10. BeiGene Ltd.
• 31.11. Janssen Biotech Inc.
• 31.12. Ionis Pharmaceuticals Inc.
• 31.13. Ayala Pharmaceuticals Inc.
• 31.14. Blueprint Medicines Corporation
• 31.15. Xencor Inc.

32. Global Desmoid Tumors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Desmoid Tumors Market

34. Recent Developments In The Desmoid Tumors Market

35. Desmoid Tumors Market High Potential Countries, Segments and Strategies

• 35.1 Desmoid Tumors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Desmoid Tumors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Desmoid Tumors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer